Assessment of Epidermal Growth Factor Receptor (EGFR) expression in human meningioma.

Published online

Journal Article

PURPOSE: This study explores whether meningioma expresses epidermal growth factor receptor (EGFR) and determines if there is a correlation between the WHO grade of this tumor and the degree of EGFR expression. METHODS: Following institutional review board approval, 113 meningioma specimens from 89 patients were chosen. Of these, 85 were used for final analysis. After a blinded review, immunohistochemical stains for EGFR were performed. Staining intensity (SI) was scored on a scale 0-3 (from no staining to strong staining). Staining percentage of immunoreactive cells (SP) was scored 1-5 (from the least to the maximum percent of the specimen staining). Immunohistochemical score (IHS) was calculated as the product of SI and SP. RESULTS: Eighty-five samples of meningioma were classified in accordance with World Health Organization (WHO) criteria: benign 57/85 (67%), atypical 23/85 (27%), and malignant 5/85 (6%). The majority of samples demonstrated a moderate SI for EGFR. IHS for EGFR demonstrated a significant association between SI and histopathologic subtype. Also, there was a correlation between the SP and histopathologic subtype (p = 0.029). A significant association was determined when the benign and the atypical samples were compared to the malignant with respect to the SP (p = 0.009). While there was a range of the IHS for the benign and the atypical histologic subtypes, malignant tumors exhibited the lowest score and were statistically different from the benign and the atypical specimens (p < 0.001). CONCLUSIONS: To our knowledge, this represents the largest series of meningioma samples analyzed for EGFR expression reported in the literature. EGFR expression is greatest in benign meningiomas and may serve a potential target for therapeutic intervention with selective EGFR inhibitors.

Full Text

Cited Authors

  • Wernicke, AG; Dicker, AP; Whiton, M; Ivanidze, J; Hyslop, T; Hammond, EH; Perry, A; Andrews, DW; Kenyon, L

Published Date

  • May 30, 2010

Published In

Volume / Issue

  • 5 /

Start / End Page

  • 46 -

PubMed ID

  • 20509969

Pubmed Central ID

  • 20509969

Electronic International Standard Serial Number (EISSN)

  • 1748-717X

Digital Object Identifier (DOI)

  • 10.1186/1748-717X-5-46


  • eng

Conference Location

  • England